Showing 2221-2230 of 5623 results for "".
- AbbVie Enters into Option Agreement with Aldeyra Therapeutics for License to Develop and Commercialize Reproxalaphttps://modernod.com/news/abbvie-enters-into-option-agreement-with-aldeyra-therapeutics-for-license-to-develop-and-commercialize-reproxalap/2481929/Aldeyra Therapeutics announced that it has entered into an exclusive option agreement with AbbVie in which AbbVie has the option to acquire a co-exclusive license to develop, manufacture, and commercialize reproxalap in the US, and an exclusive license to develop, manufacture, and comme
- SpyGlass Pharma Initiates Phase 1/2 Clinical Trial of its Intraocular Drug Delivery Platformhttps://modernod.com/news/spyglass-pharma-initiates-phase-12-clinical-trial-of-its-intraocular-drug-delivery-platform/2481924/SpyGlass Pharma announced the initiation of a phase 12 clinical trial investigating its intraocular drug delivery platform in patients with glaucoma and visually significant cataracts. The SpyGlass
- Annexon Receives PRIME Designation from the EMA for ANX007 for the Treatment of Geographic Atrophyhttps://modernod.com/news/annexon-receives-prime-designation-from-the-ema-for-anx007-for-the-treatment-of-geographic-atrophy/2481911/Annexon announced that the European Medicines Agency (EMA) has granted Priority Medicine (PRIME) designation to ANX007 for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The EMA granted this designation based on the phase 2 ARCHER
- The Vision Council and RX Announce New Host City for Vision Expo East 2025 and Future Yearshttps://modernod.com/news/the-vision-council-and-rx-announce-new-host-city-for-vision-expo-east-2025-future-years/2481903/The Vision Council and RX, co-owners of Vision Expo, announced that Vision Expo East 2025 will take place in Orlando, Florida at the Orange County Convention Center (OCCC) February 19-22, 2025. Vision Expo East’s final show in New York will occur March 14-17, 2024. Vision Exp
- Roche Stops Clinical Development of Oral Drug Candidate for Diabetic Retinopathyhttps://modernod.com/news/roche-stops-clinical-development-of-oral-drug-candidate-for-diabetic-retinopathy/2481902/Roche has decided to stop development of vicasinabin, an oral drug cadidate being evaluated for non-proliferative diabetic retinopathy, after completing phase 2 trials, according to a FiercePharma
- SpliceBio Enters Collaboration with Spark Therapeutics to Develop a Gene Therapy Targeting an Inherited Retinal Diseasehttps://modernod.com/news/splicebio-enters-collaboration-with-spark-therapeutics-to-develop-a-gene-therapy-targeting-an-inherited-retinal-disease/2481894/SpliceBio has announced the signing of an exclusive collaboration and licensing agreement with Spark Therapeutics to utilize SpliceBio’s proprietary Protein Splicing platform to develop a gene therapy for an undisclosed inherited retinal disease. Under the terms of
- Zeiss and Boehringer Ingelheim Partner to Develop Early Detection of Eye Diseases and Prevent Vision Losshttps://modernod.com/news/zeiss-and-boehringer-ingelheim-partner-to-develop-early-detection-of-eye-diseases-and-prevent-vision-loss/2481859/Zeiss Medical Technology and Boehringer Ingelheim announced a long-term strategic collaboration to develop predictive analytics to enable early detection of eye diseases and more personalized treatments to prevent vision loss for people with eye diseases. The partnership aims to bring togeth
- Melt Pharmaceuticals Announces Development and License Agreement with Catalent for Its Zydis Fast-Dissolve Technologyhttps://modernod.com/news/melt-pharmaceuticals-announces-development-and-license-agreement-with-catalent-for-its-zydis-fast-dissolve-technology/2481857/Melt Pharmaceuticals, a former subsidiary of Harrow Health, announced it has entered into an exclusive development and license agreement with Catalent in which Melt will utilize Catalent’s proprietary Zydis orally disintegrating tablet (ODT) fast-dissolve technology with MELT
- Oculus Announces Parnership with Luvo to Offer New IPL and RF Devices for the US Ophthalmic Markethttps://modernod.com/news/oculus-announces-parnership-with-luvo-to-offer-new-ipl-and-rf-devices-for-the-us-ophthalmic-market/2481853/Oculus has announced a strategic partnership with Luvo to bring new specialty care devices to the US optometry and ophthalmology market. As part of the deal, Oculus is launching the Luvo Lucent and Darwin with Intense Pulse Light and Radio Frequency therapy, which are designed to e
- Bausch + Lomb’s ONE by ONE and Biotrue Eye Care Recycling Programs Recognized As Sustainability Service of the Year Award Winnerhttps://modernod.com/news/bausch-lombs-one-by-one-and-biotrue-eye-care-recycling-programs-recognized-as-sustainability-service-of-the-year-award-winner/2481839/Bausch + Lomb announced that its ONE by ONE and Biotrue Eye Care Recycling programs have been recognized as 2023 Sustainability Award winners by Business Intelligence Group in the “Sustainability Service of the Year” category. “Millions of people wear co